Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease

NCT02850406 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02850406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02850406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Terminated
Start date
July 5, 2016
Completion date
October 2, 2023
Enrollment
147 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease